Cupid, a leading company in the production of In-Vitro Diagnostic (IVD) test kits, foresees regulatory approval for four new products in the current year. The company has experienced a substantial 82% surge in net profit in the June quarter, reaching ₹15 crore, indicating a robust performance in its IVD business segment. This growth is attributed to escalating domestic demand, an expanding international presence, and a well-defined expansion strategy that Cupid has been implementing.
Currently, Cupid offers a range of 15 IVD rapid test kits, covering crucial tests like HIV, Syphilis, Pregnancy, and Hepatitis B, with three additional kits in the pipeline. The anticipation of CE Certification for the upcoming four key products in 2025 underscores Cupid’s commitment to quality and compliance standards. The company’s successful completion of three years of production at its Maharashtra facility now enables it to participate in central and state government tenders, tapping into the escalating demand for IVD rapid tests across chemist stores, labs, and government e-Markets nationwide.
With a production capacity of 1 lakh kits per day, set to increase to 4 lakh kits per day by the end of 2026 through phased automation, Cupid is gearing up for significant scalability. The recent incorporation of a fully automated pouching machine, alongside plans for a second installation in the upcoming quarter of September, exemplifies Cupid’s strategic investment in automation to streamline production processes and enhance efficiency. Moreover, the company’s expansion efforts have already reached countries like Tanzania, Ghana, Liberia, Bangladesh, and others, driven by certification-led market entries and the rising demand for IVD solutions globally.
Aditya Kumar Halwasiya, Cupid’s Chairman and Managing Director, envisions the IVD test kits vertical as a high-impact, high-margin opportunity aligned with the company’s long-term vision of delivering quality-driven healthcare solutions at scale. Cupid’s strategic focus on automation, global certifications, and portfolio diversification underscores its commitment to addressing real diagnostic needs in diverse communities. With a strong revenue performance in the June quarter, marked by an 82% increase in net profit and a 47% rise in income, Cupid has set an ambitious revenue guidance of ₹335 crore for FY26, with a particular emphasis on the growing traction in the B2C segment during festive seasons.
In conclusion, Cupid’s proactive approach in pursuing regulatory approvals for new products, investing in automation, and expanding its global footprint signifies a promising growth trajectory for the company. By leveraging its expertise in IVD test kits and capitalizing on the increasing demand for quality healthcare solutions, Cupid is poised to emerge as a key player in the healthcare diagnostics sector, driving sustainable growth and value creation.
Key Takeaways:
– Cupid anticipates regulatory approval for four new IVD products in 2025, underscoring its commitment to quality and compliance standards.
– The company’s strategic investment in automation, with plans to increase production capacity to 4 lakh kits per day by 2026, highlights its focus on scalability and operational efficiency.
– Cupid’s revenue guidance of ₹335 crore for FY26, coupled with its expanding presence in international markets and growing traction in the B2C segment, demonstrates its strong growth prospects.
– Aditya Kumar Halwasiya’s vision of the IVD test kits vertical as a high-impact, high-margin opportunity reflects Cupid’s commitment to delivering quality-driven healthcare solutions and addressing real diagnostic needs.
Tags: regulatory, automation
Read more on thehindubusinessline.com